Project Details
| Status | Active |
|---|---|
| Effective start/end date | 5/27/15 → 5/20/26 |
Funding
- Janssen Research & Development, LLC (Prot #PCI-32765CAN3001)
Prot #PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
- Ma, Shuo (PD/PI)
Project: Research project